

# Physical Activity is Beneficial for Gallbladder Disease

Molina-Molina E<sup>1\*</sup>, Shanmugam H<sup>1\*</sup>, Wang DQH<sup>2</sup>, Vergani L<sup>3</sup> and Portincasa P<sup>1\*</sup>

<sup>1</sup>Department of Biomedical Sciences & Human Oncology, Clinica Medica “A Murri”, University of Bari Medical School, Bari, Italy

<sup>2</sup>Department of Medicine, Division of Gastroenterology and Liver Diseases, Marion Bessin Liver Research Center, Albert Einstein College of Medicine, USA

<sup>3</sup>Department of Earth, Environment and Life Sciences (DISTAV), University of Genoa, Genoa, Italy

Received: 10 Apl 2019

Accepted: 10 May 2019

Published: 17 May 2019

## \*Corresponding to:

Piero Portincasa, Department of Biomedical Sciences & Human Oncology, Clinica Medica “A. Murri”, University of Bari Medical School, Bari, Italy, Tel: +39-80-5478.227; Fax: +39-80.5478.232; E-mail: piero.portincasa@uniba.it

## 1. Abstract

Physical activity brings several beneficial effects on cardiovascular disease and in various metabolic disorders. The gallbladder is the dynamic reservoir of concentrated bile containing cholesterol, bile acids, and phospholipids as micelles and vesicles. Such lipid carriers depend on hepatic synthesis and play a key role in digestion and absorption of intestinal nutrients and cholesterol, in concert with intestinal motility. Bile acids also act as metabolically active hormones through interaction with small intestinal farnesoid-X receptor and GPBAR-1 receptor across the enterohepatic circulation. The gallbladder, however, can become the “fellow traveller” with several metabolic disorders (obesity, diabetes, insulin resistance, dyslipidaemia, nonalcoholic liver steatosis) and metabolic syndrome. In this context, aggregation and growth of excess biliary cholesterol into microcrystals and then macro-cholesterol gallstones may occur in the gallbladder. Notably, physical activity supports also benefits on the hepatobiliary tract, and via activation of bile acids acting as signalling molecules. Researchers should know that initial training condition, volume, age, intensity, aerobic capacity, body weight, and percent of body fat appear to interact with exercise-related health consequences. Thus, the overall beneficial effects of physical activity extend beyond the cardiovascular health, and involve the hepatobiliary health.

**2. Keywords:** Bile acids; Gallbladder disease; Physical activity

**3. Abbreviations:** BA; Bile acid; CVD; Cardiovascular disease; T2D; Type 2 diabetes

## 4. Introduction

Chronic diseases affect the vast majority of the elderly populations, and sedentary life contributes to the raising trend of chronic disease epidemics. This detrimental effect starts already during childhood and adolescence. Sedentary lifestyle brings negative effects on the cardiovascular system and overall health [1]. Little to no physical activity contributes to the onset of Type 2 Diabetes (T2D), Cardiovascular Disease (CVD) and premature mortality in the long-term [2]. Regular physical activity, by contrast, has beneficial effects on several chronic diseases [2], the cardiovascular system, and decreases the risk of CVD and mortality by all causes [3]. Obesity and hyperlipidaemia, as well as T2D, are components of the metabolic syndrome, a complex

aggregation of conditions further complicated by cholesterol cholelithiasis [4, 6]. The effects of physical activity, within the policy of healthier lifestyles, might also extend beyond the simple benefits on CVD, involving the hepatobiliary tract (and vice-versa).

Here, we discuss the mechanisms relating physical activity to gallbladder disease and the hepatobiliary tract.

## 5. General Aspects of Exercise

Evidences show that unfit individuals have increased risk to die (2-3 times more) at follow-up when compared with their more fit counterparts. This worrisome trend occurs regardless of body habitus, or the presence of CVD. At variance with the unmodifiable genetic, age and gender factors, physical inactivity is a modifiable risk factor. Clinicians can properly assess and prescribe -virtually to all subjects- physical activity within a structured lifestyle program.

**Table 1** depicts the exact terminology and purpose of different types of exercise. Determination of intensity of exercise allows tailoring high-intensity or moderate-intensity activities. This step requires the calculation of specific parameters. For example, Metabolic Equivalents (MET) compare the VO<sub>2</sub> produced during a certain activity with resting VO<sub>2</sub> (1 MET=3.5 mL per kg b.w./min) [7, 8]. In this context, the intensity of aerobic activity is grouped into light (2-3 METs), moderate (4-6 METs), vigorous (8-12 METs), and near maximal (14-20 METs) [9]. Notably, even moderate-intensity exercise brings significant health benefits [8]. Current guidelines in the USA, Canada, Australia and Europe for adults recommend at least 150 min/week of moderate-intensity exercise such as brisk walking) [10-14].

**Table 1:** Terminologies adopted for exercise

Type / Definition	Examples / Purpose
<b>Physical activity</b>	Jogging, walking, dancing, swimming gardening, heavy physical labor, car washing, etc.
Sustained body movement / Increased energy expenditure [8]	
<b>Exercise</b> Planned, regularly repeated, intentional physical exercise	Maintains health and fitness [8, 114]
• Aerobic (endurance) exercises	Walking, running
	Increased CV and respiratory fitness
• Strength (resistance) exercises	Weight lifting or bodyweight resistance
	Increased muscular strength
• Balance exercises	Tai chi, heel-toe walking Improved balance, proprioception Prevention of falls
• Mobility (flexibility) exercises	Yoga, stretching Maintenance or improved joint motions Muscle lengthening
<b>Physical fitness</b>	- Heath-related (CV, muscular endurance, mobility, muscular strength, body composition)
- Regular activity allowing vigorous tasks without undue fatigue	- Skill-related (balance, agility, power, coordination, reaction time)

## 6. Gallstone Disease

Cholelithiasis (either asymptomatic or symptomatic with or without the gallbladder *in situ* after cholecystectomy, with or without complications) [15, 16] is a highly prevalent condition, and one of the most expensive digestive diseases worldwide. Almost 20 million Americans (10-15% of adults in Europe and the USA) suffer from gallbladder disease [17, 18], and the raising incidence rate is 0.60-1.39% yearly [19]. The prevalence of gallstones is rising because of the increasing obesity worldwide [20, 21], metabolic syndrome [6, 22, 23], T2D [24-27] and insulin resistance [27, 28]. Additional factors include reduced high density lipoproteins (HDL) and hypertriglyceridemia [29], sedentary lifestyles [30, 31], hormone replacement therapy [30] and fast food consumption [30]. The risk of developing symptomatic gallstones prone to cholecystectomy also increases


with obesity [32-38]. As the prevalence of cholelithiasis increases worldwide (mainly because of metabolic epidemics), the chance that biliary symptoms without or with complications will develop also increases (**Table 2**).

In westernized countries, about 75% of stones consist of aggregated monohydrate cholesterol crystals, and the pathogenesis is closely related to metabolic abnormalities [17, 22]. Black pigment stones represent about 20%, and brown pigment stones only about 5% [39-42]. The most important pathogenic factors for cholesterol gallstones include (**Figure 2**):

- Genetic factors which involve lithogenic (*LITH*) genes [43, 44]
- Hepatic hypersecretion of cholesterol leading to a sustained supersaturated gallbladder bile [45]
- Rapid phase transitions of excess biliary cholesterol which results in precipitation and aggregation of solid cholesterol crystals [46, 47] (**Figure 3**)
- Defective gallbladder motility (gallbladder stasis) [48-53] with hypersecretion and luminal accumulation of mucin gel secreted by the gallbladder epithelium which is exposed to an immune-mediated inflammation [54]
- Intestinal factors involving increased absorption of cholesterol in the small intestine, slow intestinal motility, and altered gut microbiota [15, 16, 55].


**Table 2:** Clinical manifestations of gallstones

Asymptomatic gallstones
Symptomatic uncomplicated gallstones
Biliary colic
Symptomatic gallstones with complication
Acute cholecystitis*
Acute biliary pancreatitis*
Acute cholangitis*
Acute acalculous cholecystitis*
Biliary enteric fistula and gallstone ileus*
Choledocholithiasis
Cholestatic jaundice*
Cholesterosis and gallbladder polyps
Chronic cholecystitis
Gallbladder carcinoma and porcelain gallbladder
Recurrent pyogenic cholangitis*



**Figure 1:** The ternary equilibrium cholesterol-taurocholate-phosphatidylcholine phase diagram as originally depicted by Wang et al. [47].

Components appear as mole percent. The one-phase ( $\psi$ ) (micellar) zone is at the bottom, on the left is the two-phase zone (containing micelles and solid cholesterol crystals), then a central three-phase zone (containing micelles, liquid crystals and solid cholesterol crystals), and a right two-phase zone (containing micelles and liquid crystals). At the bottom, phospholipids (bile salts + phospholipids) molar ratios are also given, which is abbreviated as PL/(BS+PL). Interrupted lines indicate identical PL/(BS+PL) molar ratios, as in the case of the 3 model bile systems plotting on the line (in this case ratio of 0.2). Adapted from Portincasa P, van Erpecum KJ, Di Ciaula A, Wang DQ. The physical presence of gallstone modulates ex vivo cholesterol crystallization pathways of human bile. *Gastroenterol Rep (Oxf)* 2019; 7: 32-41 [116].



**Figure 2:** Role of physical activity appears together with lifestyle opportunities on pathogenic factors involved in the formation of cholesterol gallstones. Therapeutic interventions include also general lifestyle recommendations, dietary changes, regular physical activity, and cure and prevention of metabolic abnormalities. Excess cholesterol plays a key role at different places as solubilized molecule or solid (anhydrous, monohydrate) crystals or stones [15, 16, 45, 63, 115-117]. Adapted from: Di Ciaula A, Portincasa P. Recent advances in understanding and managing cholesterol gallstones. *F1000Res* 2018; 7: 1529.[62]

**Table 3:** Benefits of physical activity on gallbladder diseases

Author(s)	Publication type	Exercise Intervention	Main Results
Figueroide et al., 2017 [88]	Clinical Study	Vigorous physical activity	Vigorous physical activity: inverse association with risk of gallbladder disease
Li et al., 2017 [89]	Clinical Study	Aerobic capacity level	Progressively increasing aerobic capacity level: lower prevalence of gallbladder disease
Talseth et al., 2016 [90]	Clinical Study	Vigorous physical activity	Increasing the load of physical activity: reduced risk for cholecystectomy
Henaio-Moran et al., 2014 [91]	Clinical Study	General physical activity	Increasing the load of physical activity: protection against asymptomatic gallstones
Banim et al., 2010 [68]	Clinical Study	General physical activity	Highest level of physical activity: reduction of 70% in the risk of symptomatic gallstones
Williams, 2008 [92]	Clinical Study	Aerobic capacity level	Higher aerobic capacity level and speed: less risk of gallbladder disease
Shabanzadeh, 2018 [93]	Review	General physical activity	Sedentary physical activity associated with hospital admission for gallbladder disease
Aune et al., 2016 [95]	Review	General physical activity	Higher levels of physical activity inversely related to gallbladder disease
Shephard, 2015 [96]	Review	General physical activity	Potential decrease of gallstones and gallbladder cancer

## 7. Physical Activity and Gallbladder Disease

Physical activity affects gallbladder function, while decreasing the risk of gallstone disease and gallbladder disease. Mechanisms involved, however, require further elucidations with respect to cholesterol absorption, synthesis and secretion, gallbladder and intestinal motility, and neuro-hormonal aspects [56]. American Indians have a high risk of metabolic disorders and cholesterol gallstones. A previous ultrasonographic study found that physical activity related significantly and inversely to the development of gallbladder disease in a population at high risk for gallbladder disease (N=3143 subjects of both sexes, from 13 American Indian communities examined at baseline in 1989-92 and at follow-up in 1993-95). Results persisted irrespective of potential confounders (body mass index), sex, and in individuals without diabetes (not in those with diabetes) [57]. We recently reviewed the topic of lifestyles in the guidelines by the European Association for the Study of the Liver (EASL). The protective effect of physical activity on cholesterol gallstone formation is evident [20, 31, 58-61]. About 20% of gallstone patients (irrespective of the type of gallstones, i.e. cholesterol or pigment) will develop biliary symptoms, a condition which requires either medical attention or cholecystectomy [15-17, 62, 63]. In this context, questionnaire-based surveys found that physical activity is able to decrease the risk of symptomatic gallstones by one-third [31, 57, 58, 64, 65]. Two factors leading to CVD risk, such as physical inactivity and overnutrition, are precursors to increased body mass index and hepatic cholesterol synthesis rate [66]. Deposition of metabolically active visceral fat, moreover, increases gastrointestinal morbidity and mortality (due to gallstone disease, tumors, and endoscopy

complications) [67].

The European Prospective Investigation into Cancer (EPIC-Norfolk study) [68], using a validated questionnaire, investigated 25,639 volunteers (aged 40–74 years) monitored for symptomatic gallstones. Four groups of increasing physical activity were examined after 5 and 14 years. The highest level of physical activity (equivalent to exercising for 1 h a day in a sedentary job, or 30 min a day in a standing job, or heavy manual job without any additional activity) was associated with a 70% decreased risk of symptomatic gallstones in both sexes. Physical exercise appears to influence key pathogenic mechanisms of gallstone disease. Regular exercise decreases insulin levels [69] as well as insulin resistance [70]. By contrast, hyperinsulinemia promotes hepatic cholesterol uptake [71] and this situation, in turn, increases the secretion of biliary cholesterol [72], while decreasing the secretion of bile acids [73]. Notably, both conditions predispose to the accumulation of cholesterol in bile, making the environment supersaturated with excess cholesterol [62, 63]. Physical exercise has also several effects on lipid metabolism: reduces serum cholesterol and triglycerides, as shown by a large meta-analysis [74], and increases serum HDL levels [75, 76]. This effect is important since serum HDL represents a marker of reverse cholesterol transport to the liver [77], and is the precursor of bile acid synthesis [78]. In turn, this HDL-mediated pathway would participate in mechanisms leading to decreased biliary cholesterol saturation [55]. In line with this possibility, studies found that serum HDL levels are inversely related to gallstone prevalence [79]. The beneficial effects of physical exercise might also extend to the control of the fatty acid-dependent hypersecretion of gallbladder mucin [80, 81], which is another event playing a role in the pathogenesis of cholesterol cholelithiasis [17, 66, 82].

Physical activity has a prokinetic effect on the intestine [83] and appears to stimulate hormonal mechanisms, such as the cholecystokinin-dependent gallbladder contraction [84]. While keeping the ideal weight and losing excess weight is part of healthy lifestyles to prevent gallstone disease and metabolic disorders [7, 85, 86], rapid weight loss can lead to opposite effects. In fact, rapid mobilization of body cholesterol and increased secretion in bile increase the risk of gallstones formation in almost one third of the subjects [66]. Thus, the degree of obesity as well as rapidity of weight loss are crucial in developing gallstones [87].

A detailed list of benefits of physical activity performance on the gallbladder is depicted in **Table 3**. Vigorous physical activity was inversely associated with risk of gallstone disease [88]. Aerobic capacity related to prevalence of gallbladder disease; an increase in aerobic capacity by one metabolic equivalent task (MET) reduced the odd of suffering from gallbladder disease by 8% and

13%, in men and women respectively [89]. Increasing the load of vigorous physical activity was also associated with reduced risk for cholecystectomy [90], and in another study in adult women it protected against gallstones formation [91]. Similarly, higher levels of physical activity might be associated with a 70% reduction of risk for symptomatic gallstones, as reported in a five-year long study [68]. Vigorous aerobic exercise, as measured by aerobic capacity, was also inversely associated with gallbladder disease risk [92]. Hospital admission for gallbladder disease appears to be inversely associated to physical activity as well [93, 94]. Further benefits are evident by increasing the intensity of physical activity in patients with gallbladder disease, as seen for vigorous vs. non-vigorous physical activity [95]. Notably, regular aerobic exercise may favorably influence the progression of both gallstones formation and gallbladder cancer [96].

One of the main pro-kinetic effects of physical activity affecting gastrointestinal function relies on the release of cholecystokinin (CCK) [97, 98]. Not only gastrointestinal function, but also hunger has been influenced by this gastrointestinal hormone, as shown in a study involving acute exercise (from 30 to 120 min), which resulted in suppression of hunger [99]. Improvement of smooth muscle contractility by physical activity might also reinforce gallbladder emptying and refilling processes, two factors involved in the pathogenesis of gallbladder disease [52, 100]. The exact confirmation of the role of any physical activity in gallbladder disease deserves further attention. To achieve this goal fully, measurements that are more objective would be required (such as accelerometers) [57].

## 8. Bile Acid Metabolism and Physical Activity

Bile acids (BAs) are soluble amphiphiles and constitute the main lipid component of bile. BAs are synthesized from cholesterol and stored in the gallbladder particularly during fasting.

The enterohepatic circulation of BAs consists of few steps [101-103]:

- Hepatic synthesis of “primary” BAs (colic acid, CA; chenodeoxycholic acid, CDCA) from cholesterol. The essential enzymes are the rate-limiting microsomal enzyme cholesterol 7- $\alpha$ -hydroxylase (CYP7A1), the sterol 12- $\alpha$ -hydroxylase (CYP8B1) at a later step (the “classical pathway”), the sterol 27-hydroxylase (CYP27A1) (the “alternative pathway”). The synthesized BAs, after conjugation with taurine or glycine to increase their solubility, are secreted into bile and enter the gallbladder.

- With ingestion of food, cholecystokinin (CCK) plasma levels increase, as the consequence of fat-induced stimulation of upper enterocytes. CCK is a potent agonist of CCK receptors

(CCK-R) in the gallbladder smooth muscle and neurones. Activation of CCK-R stimulates gallbladder contraction and flow of bile and BAs into the duodenum (together with cholesterol and phospholipid, solubilized in 95% water as micelles and vesicles). These cholesterol carriers in bile help the intestinal digestion and absorption of lipids and fat-soluble vitamins [55, 101, 104].

- Secreted BAs undergo effective active reabsorption (>95%) in the terminal ileum into the portal vein [101]. The remaining BAs which enter the colon are transformed by the resident gut microbiome into “secondary” BAs (deoxycholic acid, DCA and lithocholic acid, LCA), and “tertiary” BAs (ursodeoxycholic acid, UDCA), which are then passively reabsorbed.

- The continuous recirculation of BAs to the liver across the portal vein is such that only 5% of daily synthesized BAs are lost into feces, while 10-50% of peripheral reabsorbed BAs undergo spillover into systemic circulation [101]. BAs act as special “hormones” because they display additional metabolic effects involving the liver, the intestine, and other tissues. BAs in the terminal ileum activate the orphan farnesoid X receptor (FXR). FXR, in turn, increases the transcription of the enterokine fibroblast growth factor 19 (FGF19 in humans) [101], with gallbladder (relaxation, refilling with freshly synthesized hepatic bile) and liver effects involving BA synthesis. BAs also activate the ileal G protein-coupled receptor (GPBAR-1), and this step leads to the secretion of peptide YY (PYY), glucagon-like peptide 1 (GLP-1) and glucagon-like peptide 2 (GLP-2). BAs help modulating the epithelial cell proliferation, gene expression, and energy, glucose, lipid and lipoprotein metabolism via activation of intestinal farnesoid X receptor (FXR) and G-protein-coupled bile acid receptor-1 (GPBAR-1), which are found in the intestine, brown adipose tissue and musculoskeletal muscle [6, 7, 101, 103, 105]. BAs also have antimicrobial and anti-inflammatory functions [101].

Physical activity could ameliorate BA metabolism by improving gastrointestinal motility (gallbladder, intestine). This aspect is still a matter of debate [106]. Previous studies in animals showed that moderate physical activity increases BA excretion [107-109]. As mentioned earlier, the recirculating FGF19 ultimately activates the hepatic FGF4 receptor/ $\beta$ -clotho and subsequent small heterodimer-mediated inhibition of BA synthesis [101]. In principle, by increasing intestinal motility, BA flow as well as FXR expression would increase. A recent study in mice, however, demonstrated that physical activity stimulates BA secretion and fecal output. This mechanism probably involves increased reverse cholesterol transport and independent upregulation of genes involved in BA synthesis, as well as FXR-FGF19 feedback [110].

Additional mechanisms include metabolic post-transcriptional pathways (increased fatty acid absorption). In the clinical setting, however, both fecal and serum BA concentrations decreased significantly in runners [111, 112], but the study did not investigate FXR function. It is still unknown whether physical activity might be able to produce additional BA/GPBAR-1-mediated metabolic or anti-inflammatory effects, due to an apparent lack of translational results from clinical to animal studies.

## 9. Conclusion and Future Perspectives

In general, physical activity is the only valid scientific therapeutic approach to counteract sedentary dysfunctions as well as the increasing trends of several chronic diseases [2]. Physical activity should be an integral component of healthy lifestyles aimed at maintaining the ideal weight, to achieve the ideal weight or – in subjects unable to attain and maintain substantial weight reduction – to plan a modest weight loss ( $\leq 10\%$ ) [113]. Beside the numerous beneficial metabolic and cardiovascular effects, physical activity targets also the biliary tract. This aspect raises the possibility that physical activity (many possibilities investigated so far) would play a role as therapeutic tool in primary (and secondary) prevention of gallbladder disease (i.e. gallbladder hypomotility, gallstone disease, symptomatic gallstones and subsequent cholecystectomy). The benefits of physical activity might extend to the gastrointestinal function and the enterohepatic re-circulation of bile acids acting as hormone-like signaling agents and undergoing continuous enterohepatic recirculation. Further research should explore measurements that are more accurate, in order to dissect distinctive outcomes of each physical activity modality. Future studies should also explore the main beneficial and harmful effects of physical activity in cohorts exposed to different nutrition intake, weight changes, or initial physical condition of the individual.

## 10. Acknowledgement

The present chapter is written in the context of the project FOIE GRAS, which has received funding from the European Union’s Horizon 2020 Research and Innovation programme under the Marie Skłodowska-Curie Grant Agreement No. 722619. \*EMM and HS are recipients of Foie Gras Early Research Training Grant.

## References

1. Ruiz JR, Labayen I, Ortega FB, Moreno LA, Rodriguez G, Breidenassel C et al. Physical activity, sedentary time, and liver enzymes in adolescents: the HELENA study. *Pediatr Res.* 2014; 75: 798 - 802.
2. Booth FW, Roberts CK and Laye MJ. Lack of exercise is a major cause of chronic diseases. *Compr Physiol.* 2012;2:1143-211.
3. Kodama S, Saito K, Tanaka S, Maki M, Yachi Y, Asumi M et al. Cardiorespiratory fitness as a quantitative predictor of all-cause mortality and cardiovascular events in healthy men and women: a meta-analysis. *JAMA.* 2009;301:2024-35.
4. Loria P, Lonardo A, Lombardini S, Carulli L, Verrone A, Ganazzi D et al. Gallstone disease in non-alcoholic fatty liver: prevalence and associated factors. *J Gastroenterol Hepatol.* 2005;20:1176-84.
5. Garruti G, Wang DQ, Di Ciaula A and Portincasa P. Cholecystectomy: a way forward and back to metabolic syndrome? *Lab Invest.* 2018;98:4-6.
6. Di Ciaula A, Garruti G, Wang DQ and Portincasa P. Cholecystectomy and risk of metabolic syndrome. *Eur J Intern Med.* 2018;53:3-11.
7. Molina-Molina E, Lunardi Baccetto R, Wang DQ, de Bari O, Krawczyk M, Portincasa P et al. Exercising the hepatobiliary-gut axis. The impact of physical activity performance. *Eur J Clin Invest.* 2018;48:e12958.
8. Kenney WL, Wilmore JH and Costill DL. *Medicine ACSM. ACSM's Guidelines for Exercise Testing and Prescription.* Baltimore: 2013.
9. *Physiology of sport and exercise: Human kinetics:* 2018.
10. Australian Government Department of Health. Australia's Physical Activity and Sedentary Behaviour Guidelines and the Australian 24-Hour Movement Guidelines (<http://www.health.gov.au/internet/main/publishing.nsf/content/health-pubhlth-strateg-phys-actguidelines>): 2013.
11. Oja P, Bull FC, Fogelholm M and Martin BW. Physical activity recommendations for health: what should Europe do? *BMC Public Health.* 2010;10:10.
12. Warburton DE, Charlesworth S, Ivey A, Nettlefold L and Bredin SS. A systematic review of the evidence for Canada's Physical Activity Guidelines for Adults. *Int J Behav Nutr Phys Act.* 2010;7:39.
13. Tremblay MS, Warburton DE, Janssen I, Paterson DH, Latimer AE, Rhodes RE et al. New Canadian physical activity guidelines. *Appl Physiol Nutr Metab.* 2011; 36(1): 36-46; 47 - 58.
14. Piercy KL, Troiano RP, Ballard RM, Carlson SA, Fulton JE, Galuska DA et al. The Physical Activity Guidelines for Americans. *JAMA.* 2018;320:2020-8.
15. Gallstones. In: Podolsky KD, Camilleri M, Fitz JG, Kalloo AN, Shanahan F and Wang TC, et al. editors. *Yamada's Textbook of Gastroenterology.* Hoboken, New Jersey (USA): Wiley-Blackwell. 2015; 1808-34.
16. Portincasa P, Wang DQH. Gallstones. In: Podolsky KD, Camilleri M, Fitz JG, Kalloo AN, Shanahan F and Wang TC, editors. *Yamada's Atlas of Gastroenterology.* Hoboken, New Jersey (USA): Wiley-Blackwell. 2016; 335-53.
17. Portincasa P, Moschetta A, Palasciano G. Cholesterol gallstone disease. *Lancet.* 2006;368:230-9.
18. Wang DQH, Portincasa P and (Editors). *Gallstones. Recent advances in epidemiology, pathogenesis, diagnosis and management. The first edition.* New York, NY: Nova Science Publisher Inc.: 2017 pp. 1-676 pp. 1-676.
19. Shabanzadeh DM. Incidence of gallstone disease and complications. *Curr Opin Gastroenterol.* 2018;34:81-9.
20. European Association for the Study of the L. *EASL Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones.* *J Hepatol.* 2016;65(1):146-81.
21. Friedman GD, Kannel WB and Dawber TR. The epidemiology of gallbladder disease: observations in the Framingham Study. *J Chronic Dis.* 1966;19:273-92.
22. Grundy SM. Cholesterol gallstones: a fellow traveler with metabolic syndrome? *Am J Clin Nutr.* 2004;80:1-2.
23. Chen LY, Qiao QH, Zhang SC, Chen YH, Chao GQ, Fang LZ et al. Metabolic syndrome and gallstone disease. *World J Gastroenterol.* 2012;18:4215-20.
24. Ruhl CE and Everhart JE. Association of diabetes, serum insulin, and C-peptide with gallbladder disease. *Hepatology* 2000;31:299-303.
25. Haffner SM, Diehl AK, Mitchell BD, Stern MP and Hazuda HP. Increased prevalence of clinical gallbladder disease in subjects with non-insulin-dependent diabetes mellitus. *Am J Epidemiol.* 1990;132:327-35.
26. Misciagna G, Guerra V, Di Leo A, Correale M and Trevisan M. Insulin and gall stones: a population case control study in southern Italy. *Gut.* 2000;47:144-7.
27. Weikert C, Weikert S, Schulze MB, Pischon T, Fritsche A, Bergmann MM et al. Presence of gallstones or kidney stones and risk of type 2 diabetes. *Am J Epidemiol.* 2010;171:447-54.
28. Biddinger SB, Haas JT, Yu BB, Bezy O, Jing E, Zhang W et al. Hepatic insulin resistance directly promotes formation of cholesterol

gallstones. *Nat Med.* 2008;14:778-82.

29. Banim PJ, Luben RN, Bulluck H, Sharp SJ, Wareham NJ, Khaw KT et al. The aetiology of symptomatic gallstones quantification of the effects of obesity, alcohol and serum lipids on risk. *Epidemiological and biomarker data from a UK prospective cohort study (EPIC-Norfolk).* *Eur J Gastroenterol Hepatol.* 2011;23:733-40.

30. Stender S, Nordestgaard BG and Tybjaerg-Hansen A. Elevated body mass index as a causal risk factor for symptomatic gallstone disease: a Mendelian randomization study. *Hepatology.* 2013;58:2133-41.

31. Leitzmann MF, Rimm EB, Willett WC, Spiegelman D, Grodstein F, Stampfer MJ et al. Recreational physical activity and the risk of cholecystectomy in women. *N Engl J Med.* 1999;341:777-84.

32. The epidemiology of gallstone disease in Rome, Italy. Part I. Prevalence data in men. The Rome Group for Epidemiology and Prevention of Cholelithiasis (GREPCO). *Hepatology.* 1988;8:904-6.

33. Volzke H, Baumeister SE, Alte D, Hoffmann W, Schwahn C, Simon P et al. Independent risk factors for gallstone formation in a region with high cholelithiasis prevalence. *Digestion.* 2005;71:97-105.

34. Maclure KM, Hayes KC, Colditz GA, Stampfer MJ, Speizer FE, Willett WC, et al. Weight, diet, and the risk of symptomatic gallstones in middle-aged women. *N Engl J Med.* 1989;321:563-9.

35. Tsai CJ, Leitzmann MF, Willett WC and Giovannucci EL. Central adiposity, regional fat distribution, and the risk of cholecystectomy in women. *Gut.* 2006;55:708-14.

36. Klein S, Wadden T and Sugerman HJ. AGA technical review on obesity. *Gastroenterology.* 2002;123:882-932.

37. Scragg RK, McMichael AJ and Baghurst PA. Diet, alcohol, and relative weight in gall stone disease: a case-control study. *Br Med J (Clin Res Ed).* 1984;288:1113-9.

38. Stampfer MJ, Maclure KM, Colditz GA, Manson JE and Willett WC. Risk of symptomatic gallstones in women with severe obesity. *Am J Clin Nutr.* 1992;55:652-8.

39. Diehl AK. Epidemiology and natural history of gallstone disease. *Gastroenterol Clin North Am.* 1991;20:1-19.

40. Sherlock S and Dooley J. Diseases of the liver and biliary system. Oxford: Blackwell Science: 2002; 52(4): 597-628.

41. Trotman BW, Ostrow JD and Soloway RD. Pigment vs cholesterol cholelithiasis: comparison of stone and bile composition. *Am J Dig Dis.* 1974;19:585-90.

42. Attili AF, Carulli N, Roda E, Barbara B, Capocaccia L, Menotti A

et al. Epidemiology of gallstone disease in Italy: prevalence data of the Multicenter Italian Study on Cholelithiasis (M.I.COL.). *Am J Epidemiol.* 1995;141:158-65.

43. Lammert F, Wang DQ, Wittenburg H, Bouchard G, Hillebrandt S, Taenzler B et al. Lith genes control mucin accumulation, cholesterol crystallization, and gallstone formation in A/J and AKR/J inbred mice. *Hepatology.* 2002;36:1145-54.

44. Wang DQ and Afdhal NH. Genetic analysis of cholesterol gallstone formation: searching for Lith (gallstone) genes. *Curr Gastroenterol Rep.* 2004;6:140-50.

45. Wang TY, Portincasa P, Liu M, Tso P and Wang DQ. Mouse models of gallstone disease. *Curr Opin Gastroenterol.* 2017.

46. Sedaghat A and Grundy SM. Cholesterol crystals and the formation of cholesterol stones. *N Engl J Med.* 1980;302:1274-7.

47. Wang DQH and Carey MC. Complete mapping of crystallization pathways during cholesterol precipitation from model bile: Influence of physical-chemical variables of pathophysiologic relevance and identification of a stable liquid crystalline state in cold, dilute and hydrophilic bile salt-containing systems. *Journal of Lipid Research.* 1996;37:606-30.

48. Di Ciaula A, Wang DQ and Portincasa P. Gallbladder and gastric motility in obese newborns, pre-adolescents and adults. *J Gastroenterol Hepatol.* 2012;27:1298-305.

49. Vezina WC, Paradis RL, Grace DM, Zimmer RA, Lamont DD, Rycroft KM et al. Increased volume and decreased emptying of the gallbladder in large (morbidly obese, tall normal, and muscular normal) people. *Gastroenterology.* 1990;98:1000-7.

50. Di Ciaula A, Molina-Molina E, Bonfrate L, Wang DQ, Dumitrascu DL and Portincasa P. Gastrointestinal defects in gallstone and cholecystectomized patients. *Eur J Clin Invest.* 2019;49:e13066.

51. Portincasa P, Di Ciaula A, Wang HH, Palasciano G, van Erpecum KJ, Moschetta A et al. Coordinate regulation of gallbladder motor function in the gut-liver axis. *Hepatology.* 2008; 47(6): 2112-26.

52. Portincasa P, Di Ciaula A, Baldassarre G, Palmieri V, Gentile A, Cimmino A et al. Gallbladder motor function in gallstone patients: sonographic and in vitro studies on the role of gallstones, smooth muscle function and gallbladder wall inflammation. *J Hepatol.* 1994; 21(3): 430-40.

53. Portincasa P, Di Ciaula A, Vendemiale G, Palmieri V, Moschetta A, Vanberge-Henegouwen GP et al. Gallbladder motility and cholesterol crystallization in bile from patients with pigment and cholesterol

- gallstones. *Eur J Clin Invest.* 2000; 30: 317-24.
54. Grattagliano I, Wang DQ, Di CA, Diogo CV, Palasciano G and Portincasa P. Biliary proteins and their redox status changes in gallstone patients. *Eur J Clin Invest.* 2009; 39: 986-92.
55. Wang DQH, Neuschwander-Tetri BA and Portincasa P. *The Biliary System*, Second Edition, vol. 8. San Rafael, CA (USA): Morgan & Claypool Life Sciences. 2017 pp. i-178.
56. Utter AC, Whitcomb DC, Nieman DC, Butterworth DE and Vermillion SS. Effects of exercise training on gallbladder function in an obese female population. *Med Sci Sports Exerc.* 2000; 32: 41-5.
57. Kriska AM, Brach JS, Jarvis BJ, Everhart JE, Fabio A, Richardson CR et al. Physical activity and gallbladder disease determined by ultrasonography. *Med Sci Sports Exerc.* 2007; 39: 1927-32.
58. Leitzmann MF, Giovannucci EL, Rimm EB, Stampfer MJ, Spiegelman D, Wing AL et al. The relation of physical activity to risk for symptomatic gallstone disease in men. *Ann Intern Med.* 1998; 128: 417-25.
59. Misciagna G, Centonze S, Leoci C, Guerra V, Cisternino AM, Ceo R et al. Diet, physical activity, and gallstones—a population-based, case-control study in southern Italy. *Am J Clin Nutr.* 1999; 69: 120-6.
60. Walcher T, Haenle MM, Mason RA, Koenig W, Imhof A, Kratzer W et al. The effect of alcohol, tobacco and caffeine consumption and vegetarian diet on gallstone prevalence. *Eur J Gastroenterol Hepatol.* 2010; 22: 1345-51.
61. Ortega RM, Fernandez-Azuela M, Encinas-Sotillos A, Andres P and Lopez-Sobaler AM. Differences in diet and food habits between patients with gallstones and controls. *J Am Coll Nutr.* 1997; 16: 88-95.
62. Di Ciaula A and Portincasa P. Recent advances in understanding and managing cholesterol gallstones. *F1000Res.* 2018; 7: 1529.
63. Di Ciaula A, Wang DQ and Portincasa P. An update on the pathogenesis of cholesterol gallstone disease. *Curr Opin Gastroenterol.* 2018; 34: 71-80.
64. Storti KL, Brach JS, FitzGerald SJ, Zmuda JM, Cauley JA and Kriska AM. Physical activity and decreased risk of clinical gallstone disease among post-menopausal women. *Prev Med.* 2005; 41: 772-7.
65. Kato I and Tominaga S. [Factors associated with levels of physical activity at work and during leisure time]. *Nihon Koshu Eisei Zasshi.* 1992; 39: 822-9.
66. Lammert F, Gurusamy K, Ko CW, Miquel JF, Mendez-Sanchez N, Portincasa P et al. Gallstones. *Nat Rev Dis Primers.* 2016; 2: 16024.
67. Farrell GC. The liver and the waistline: Fifty years of growth. *J Gastroenterol Hepatol.* 2009; 24: S105-18.
68. Banim PJ, Luben RN, Wareham NJ, Sharp SJ, Khaw KT and Hart AR. Physical activity reduces the risk of symptomatic gallstones: a prospective cohort study. *Eur J Gastroenterol Hepatol.* 2010; 22: 983-8.
69. Kirwan JP, Kohrt WM, Wojta DM, Bourey RE and Holloszy JO. Endurance exercise training reduces glucose-stimulated insulin levels in 60- to 70-year-old men and women. *J Gerontol.* 1993; 48: M84-90.
70. Seals DR, Hagberg JM, Hurley BF, Ehsani AA and Holloszy JO. Effects of endurance training on glucose tolerance and plasma lipid levels in older men and women. *JAMA.* 1984; 252: 645-9.
71. Chait A, Bierman EL and Albers JJ. Low-density lipoprotein receptor activity in cultured human skin fibroblasts. Mechanism of insulin-induced stimulation. *J Clin Invest.* 1979; 64: 1309-19.
72. Nepokroeff CM, Lakshmanan MR, Ness GC, Dugan RE and Porter JW. Regulation of the diurnal rhythm of rat liver beta-hydroxy-beta-methylglutaryl coenzyme A reductase activity by insulin, glucagon, cyclic AMP and hydrocortisone. *Arch Biochem Biophys.* 1974; 160: 387-96.
73. Subbiah MT and Yunker RL. Cholesterol 7 alpha-hydroxylase of rat liver: an insulin sensitive enzyme. *Biochem Biophys Res Commun.* 1984; 124: 896-902.
74. Tran ZV, Weltman A, Glass GV and Mood DP. The effects of exercise on blood lipids and lipoproteins: a meta-analysis of studies. *Med Sci Sports Exerc.* 1983; 15: 393-402.
75. Leon AS and Sanchez OA. Response of blood lipids to exercise training alone or combined with dietary intervention. *Med Sci Sports Exerc.* 2001; 33: S502-15.
76. Baker TT, Allen D, Lei KY and Willcox KK. Alterations in lipid and protein profiles of plasma lipoproteins in middle-aged men consequent to an aerobic exercise program. *Metabolism.* 1986; 35: 1037-43.
77. Gupta AK, Ross EA, Myers JN and Kashyap ML. Increased reverse cholesterol transport in athletes. *Metabolism.* 1993; 42: 684-90.
78. Halloran LG, Schwartz CC, Vlahcevic ZR, Nisman RM and Swell L. Evidence for high-density lipoprotein-free cholesterol as the primary precursor for bile-acid synthesis in man. *Surgery.* 1978; 84: 1-7.
79. Petitti DB, Friedman GD and Klatsky AL. Association of a history of gallbladder disease with a reduced concentration of high-density-lipoprotein cholesterol. *N Engl J Med.* 1981; 304: 1396-8.
80. Mingrone G, Greco AV and Arcieri Mastromattei E. Free fatty acids stimulate mucin hypersecretion by rabbit gallbladder epithelium in



vitro. *Clin Sci*. 1990; 78: 175-80.

81. Mingrone G, Greco AV, Finotti E and Passi S. Free fatty acids: a stimulus for mucin hypersecretion in cholesterol gallstone biles. *Biochim Biophys Acta*. 1988; 958: 52-9.

82. Wang HH, Portincasa P and Wang DQ. Molecular pathophysiology and physical chemistry of cholesterol gallstones. *Front Biosci*. 2008; 13: 401-23.

83. Koffler KH, Menkes A, Redmond RA, Whitehead WE, Pratley RE and Hurley BF. Strength training accelerates gastrointestinal transit in middle-aged and older men. *Med Sci Sports Exerc*. 1992; 24: 415-9.

84. Philipp E, Wilckens T, Friess E, Platte P and Pirke KM. Cholecystokinin, gastrin and stress hormone responses in marathon runners. *Peptides*. 1992; 13: 125-8.

85. Bonfrate L, Wang DQ, Garruti G and Portincasa P. Obesity and the risk and prognosis of gallstone disease and pancreatitis. *Best Pract Res Clin Gastroenterol*. 2014; 28: 623-35.

86. Faienza MF, Wang DQ, Fruhbeck G, Garruti G and Portincasa P. The dangerous link between childhood and adulthood predictors of obesity and metabolic syndrome. *Intern Emerg Med*. 2016; 11:175-82.

87. Heida A, Koot BG, vd Baan-Slootweg OH, Pels Rijcken TH, Seidell JC, Makkes S et al. Gallstone disease in severely obese children participating in a lifestyle intervention program: incidence and risk factors. *Int J Obes (Lond)*. 2014; 38: 950-3.

88. Figueiredo JC, Haiman C, Porcel J, Buxbaum J, Stram D, Tambe N et al. Sex and ethnic/racial-specific risk factors for gallbladder disease. *BMC Gastroenterol* 2017; 17: 153.

89. Li C, Mikus C, Ahmed A, Hu G, Xiong K, Zhang Y et al. A cross-sectional study of cardiorespiratory fitness and gallbladder disease. *Ann Epidemiol*. 2017; 27: 269-73 e3.

90. Talseth A, Ness-Jensen E, Edna TH and Hveem K. Risk factors for requiring cholecystectomy for gallstone disease in a prospective population-based cohort study. *Br J Surg*. 2016; 103: 1350-7.

91. Henao-Moran S, Denova-Gutierrez E, Moran S, Duque X, Gallegos-Carrillo K, Macias N et al. Recreational physical activity is inversely associated with asymptomatic gallstones in adult Mexican women. *Ann Hepatol*. 2014; 13: 810-8.

92. Williams PT. Independent effects of cardiorespiratory fitness, vigorous physical activity, and body mass index on clinical gallbladder disease risk. *Am J Gastroenterol*. 2008; 103: 2239-47.

93. Shabanzadeh DM. New determinants for gallstone disease?. *Dan Med J*. 2018; 65.

94. Shabanzadeh DM, Sorensen LT and Jorgensen T. Determinants for clinical events in gallstone carriers unaware of their gallstones. *J Gastroenterol Hepatol*. 2017; 32: 721-6.

95. Aune D, Leitzmann M and Vatten LJ. Physical Activity and the Risk of Gallbladder Disease: A Systematic Review and Meta-Analysis of Cohort Studies. *J Phys Act Health*. 2016; 13: 788-95.

96. Shephard RJ. Physical Activity and the Biliary Tract in Health and Disease. *Sports Med* 2015; 45: 1295-1309.

97. Utter A and Goss F. Exercise and gall bladder function. *Sports Med*. 1997; 23: 218-27.

98. Krishnamurthy S and Krishnamurthy GT. Biliary dyskinesia: role of the sphincter of Oddi, gallbladder and cholecystokinin. *J Nucl Med*. 1997; 38: 1824-30.

99. Schubert MM, Desbrow B, Sabapathy S and Leveritt M. Acute exercise and subsequent energy intake. A meta-analysis. *Appetite*. 2013; 63: 92-104.

100. Portincasa P, Di Ciaula A and vanBerge-Henegouwen GP. Smooth muscle function and dysfunction in gallbladder disease. *Curr Gastroenterol Rep*. 2004; 6: 151-62.

101. Di Ciaula A, Garruti G, Lunardi Baccetto R, Molina-Molina E, Bonfrate L, Wang DQ et al. Bile Acid Physiology. *Ann Hepatol*. 2017; 16: 3-105.

102. Di Ciaula A, Wang DQ, Molina-Molina E, Lunardi Baccetto R, Calamita G, Palmieri VO et al. Bile Acids and Cancer: Direct and Environmental-Dependent Effects. *Ann Hepatol* 2017; 16: 87-105.

103. Garruti G, Di Ciaula A, Wang HH, Wang DQ and Portincasa P. Cross-Talk Between Bile Acids and Gastro-Intestinal and Thermogenic Hormones: Clues from Bariatric Surgery. *Ann Hepatol*. 2017; 16: s68-s82.

104. Li T and Chiang JY. Bile acid signaling in metabolic disease and drug therapy. *Pharmacol Rev*. 2014; 66: 948-83.

105. Brighton CA, Rievaj J, Kuhre RE, Glass LL, Schoonjans K, Holst JJ et al. Bile Acids Trigger GLP-1 Release Predominantly by Accessing Basolaterally Located G Protein-Coupled Bile Acid Receptors. *Endocrinology*. 2015; 156: 3961-70.

106. Peters HP, De Vries WR, Vanberge-Henegouwen GP and Akkermans LM. Potential benefits and hazards of physical activity and exercise on the gastrointestinal tract. *Gut*. 2001; 48: 435-9.

107. Yiamouyiannis CA, Martin BJ and Watkins JB 3rd. Chronic physical activity alters hepatobiliary excretory function in rats. *J Pharmacol Exp Ther*. 1993; 265: 321-7.

108. Watkins JB 3rd, Crawford ST and Sanders RA. Chronic voluntary exercise may alter hepatobiliary clearance of endogenous and exogenous chemicals in rats. *Drug Metab Dispos.* 1994; 22: 537-43.
109. Bouchard G, Carrillo MC, Tuchweber B, Perea A, Ledoux M, Poulin D et al. Moderate longterm physical activity improves the age-related decline in bile formation and bile salt secretion in rats. *Proc Soc Exp Biol Med.* 1994; 206: 409-15.
110. Meissner M, Lombardo E, Havinga R, Tietge UJ, Kuipers F and Groen AK. Voluntary wheel running increases bile acid as well as cholesterol excretion and decreases atherosclerosis in hypercholesterolemic mice. *Atherosclerosis.* 2011; 218: 323-9.
111. Sutherland WH, Nye ER, Macfarlane DJ, Robertson MC and Williamson SA. Fecal bile acid concentration in distance runners. *Int J Sports Med.* 1991; 12: 533-6.
112. Danese E, Salvagno GL, Tarperi C, Negrini D, Montagnana M, Festa L et al. Middle-distance running acutely influences the concentration and composition of serum bile acids: Potential implications for cancer risk?. *Oncotarget.* 2017; 8: 52775-82.
113. Goldstein DJ. Beneficial health effects of modest weight loss. *Int J Obes Relat Metab Disord.* 1992; 16: 397-415.
114. NIH. Go4Life from the National Institute on Aging at the National Institute of Health (NIH). (accessed April 2019).
115. Portincasa P, Molina-Molina E, Garruti G and Wang DQ. Critical Care Aspects of Gallstone Disease. *J Crit Care Med (Targu Mures).* 2019; 5: 6-18.
116. Portincasa P, van Erpecum KJ, Di Ciaula A and Wang DQ. The physical presence of gallstone modulates ex vivo cholesterol crystallization pathways of human bile. *Gastroenterol Rep (Oxf).* 2019; 7: 32-41.
117. Di Ciaula A, Garruti G, Fruhbeck G, De Angelis M, De Bari O, D Q-H Wang D et al. The Role Of Diet In The Pathogenesis Of Cholesterol Gallstones. *Curr Med Chem.* 2017; 29.